Výsledky vyhledávání - "R. E. Millikan"

Bladder Cancer Predisposition: A Multigenic Approach to DNA-Repair and Cell-Cycle–Control Genes

Autor: H. Barton Grossman, Maosheng Huang, R. E. Millikan, Xifeng Wu, Christopher I. Amos, Carol J. Etzel, Margaret R. Spitz, Seth P. Lerner, Qing Zhang, Colin P.N. Dinney, Jian Gu

Publikováno v: The American Journal of Human Genetics. 78:464-479

The candidate-gene approach in association studies of polygenic diseases has often yielded conflicting results. In this hospital-based case-control study with 696 white patients newly diagnosed with bladder cancer and 629 unaffected white controls, w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccec354bc295aa6cf60605ea1242fd55
https://doi.org/10.1086/500848

Zobrazit plný text záznamu

Polymorphisms in Inflammation Genes and Bladder Cancer: From Initiation to Recurrence, Progression, and Survival

Autor: Seth P. Lerner, Jian Gu, Qiong Dong, Yunfei Wang, Dan Leibovici, R. E. Millikan, Colin P.N. Dinney, H. Barton Grossman, Xifeng Wu

Publikováno v: Journal of Clinical Oncology. 23:5746-5756

Purpose Since chronic inflammation contributes to tumorigenesis, we hypothesized that the risk and clinical outcome of bladder cancer (BC) might be modulated by genetic variations in inflammation genes. Methods Using the TaqMan method, we genotyped s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cefcb78dcc22b6e28be5f81efc0ce7f
https://doi.org/10.1200/jco.2005.01.598

Zobrazit plný text záznamu

The bile acid–activated phosphatidylinositol 3-kinase pathway inhibits Fas apoptosis upstream of bid in rodent hepatocytes

Autor: Patricia J. Roberts, Hideyuki Miyoshi, Yasuhiro Takikawa, Christian Rust, Pijus K. Mandal, Gregory J. Gores, R. E. Millikan, Richard M. Siegel

Publikováno v: Gastroenterology. 120:1810-1817

Backgrounds & Aims: Bile acids differentially modulate hepatocyte injury in cholestasis. Although glycochenodeoxycholate (GCDC) induces Fas-mediated hepatocyte apoptosis, taurochenodeoxycholate (TCDC) simultaneously activates a phosphatidylinositol 3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab1bc08043ba3ab99612432c8fa1b486
https://doi.org/10.1053/gast.2001.24835

Zobrazit plný text záznamu

Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival

Autor: Alberto J. Montero, Jingjing Liu, C. M. Diaz-Montero, Eric Jonasch, Patrick Hwu, R. E. Millikan, B. W. McIntyre, Kim Anh Do, S. Hodges, Nizar M. Tannir

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology. 20(10)

Background: To correlate serum cytokine and angiogenic factor (CAF) levels with overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with interferon-α (IFN-α). Patients and methods: Serum CAF levels were measured in 103 patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a11837971442288be411903ca7900947
https://pubmed.ncbi.nlm.nih.gov/19541791

Zobrazit plný text záznamu

Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin

Autor: R E, Millikan, W K, Plunkett, T L, Smith, D L, Williams, C J, Logothetis

Publikováno v: Cancer. 92(1)

The authors investigated the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) associated with the addition of a biomodulating dose of gemcitabine to an established regimen of ifosfamide and doxorubicin as part of a program to explore the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::17e46e4f6ccc6055d33743d5f4d06a15
https://pubmed.ncbi.nlm.nih.gov/11443627

Zobrazit plný text záznamu

Evaluating multiple treatment courses in clinical trials

Autor: P F, Thall, R E, Millikan, H G, Sung

Publikováno v: Statistics in medicine. 19(8)

In oncology, a patient's treatment often involves multiple courses of chemotherapy. The most common medical practice in choosing treatments for successive courses is to repeat a treatment that is successful in a given course and otherwise switch to a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::476350cc3f59b72c216d3508a1f9985e
https://pubmed.ncbi.nlm.nih.gov/10790677

Zobrazit plný text záznamu

Chemotherapy of advanced prostatic carcinoma

Autor: R E, Millikan

Publikováno v: Seminars in oncology. 26(2)

Metastatic prostate cancer remains incurable. Historically, therapy options for patients with nonlocalized disease have been limited to hormonal therapy and palliative radiation therapy. The use of cytotoxic chemotherapy has not been routine, and is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c751ecbe2717b502e89a10ff9bf4ddec
https://pubmed.ncbi.nlm.nih.gov/10597729

Zobrazit plný text záznamu

Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer

Autor: J A, Ellerhorst, S M, Tu, R J, Amato, L, Finn, R E, Millikan, L C, Pagliaro, A, Jackson, C J, Logothetis

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 3(12 Pt 1)

Two distinct regimens of weekly chemotherapy for hormone-refractory prostate cancer were combined in an alternating schedule and tested in a Phase II trial to determine efficacy and toxic effects. Forty-six patients with hormone-refractory prostate c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0dc36a70d15f4f6d0b1b2ea39df9864a
https://pubmed.ncbi.nlm.nih.gov/9815636

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání